Physician profile
Dustan Osborn
NPI 1528061132
$4,140.04
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,115 · 2020: $522 · 2021: $275 · 2022: $157 · 2023: $70.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $710.16 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $532.40 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $397.15 | 2019-2022 | |
| Janssen Biotech, INC. | $260.13 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $239.95 | 2019-2021 | |
| Genentech USA, INC. | $229.05 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $166.40 | 2019-2020 | |
| Lilly USA, LLC | $164.55 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $148.14 | 2019-2020 | |
| Emd Serono, INC. | $129.15 | 2019-2020 | |
| Clovis Oncology, INC. | $105.10 | 2019 | |
| Abbvie INC. | $100.98 | 2019 | |
| Pfizer INC. | $83.70 | 2019-2020 | |
| Ge Healthcare | $70.40 | 2023 | |
| Daiichi Sankyo INC. | $63.60 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $62.57 | 2019 | |
| Myovant Sciences INC. | $56.10 | 2021 | |
| Taiho Oncology, INC. | $53.56 | 2019 | |
| Genzyme Corporation | $52.21 | 2019 | |
| Seagen INC. | $49.63 | 2019-2020 | |
| Exelixis INC. | $47.38 | 2019 | |
| Incyte Corporation | $40.82 | 2019-2022 | |
| Eisai INC. | $40.76 | 2019-2022 | |
| Agios Pharmaceuticals, INC. | $39.37 | 2019 | |
| Merck Sharp & Dohme LLC | $36.92 | 2019 | |
| Mylan Institutional INC. | $36.02 | 2019 | |
| Astellas Pharma US INC | $34.88 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $26.47 | 2022 | |
| Amag Pharmaceuticals, INC. | $24.38 | 2021 | |
| Celgene Corporation | $23.74 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.77 | 2019 | |
| Adc Therapeutics America, INC. | $20.59 | 2022 | |
| Array Biopharma INC | $15.53 | 2020 | |
| Amgen INC. | $14.66 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $14.52 | 2019 | |
| Secura Bio, INC. | $14.38 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dustan Osborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.